Alemtuzumab as compared to alternative contemporary induction regimens

Transplant International

Volumn 25, Issue 5, 2012, Pages 518-526

  Lamattina, John C ^a   Mezrich, Joshua D ^b   Michael Hofmann, R ^b   Foley, David P ^b   D'Alessandro, Anthony M ^b   Sollinger, Hans W ^b   Pirsch, John D ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

alemtuzumab; anti thymocyte globulin; basiliximab; renal transplantation

Indexed keywords

ACICLOVIR; ALEMTUZUMAB; BASILIXIMAB; CLOTRIMAZOLE; COTRIMOXAZOLE; CYCLOSPORIN A; DEXAMETHASONE; HLA ANTIGEN; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; NYSTATIN; PREDNISONE; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ADULT; AGE; ANTIBODY MEDIATED GRAFT REJECTION; ANTIVIRAL THERAPY; ARTICLE; BACTERIAL INFECTION; CANDIDIASIS; COHORT ANALYSIS; CYTOMEGALOVIRUS INFECTION; DONOR; DRUG DOSE REDUCTION; FEMALE; GRAFT RECIPIENT; GRAFT REJECTION; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY ALLOGRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LIVING DONOR; LOW DRUG DOSE; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MYCOSIS; OPPORTUNISTIC INFECTION; OVERALL SURVIVAL; PNEUMOCYSTOSIS; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; SINGLE DRUG DOSE; STEROID THERAPY; SURVIVAL RATE; SURVIVAL TIME; VIRUS INFECTION;

ADULT; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTILYMPHOCYTE SERUM; FEMALE; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INFECTION; KAPLAN-MEIER ESTIMATE; KIDNEY TRANSPLANTATION; LEUKOPENIA; MALE; MIDDLE AGED; RECOMBINANT FUSION PROTEINS; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT OUTCOME;

EID: 84859705461     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2012.01448.x     Document Type: Article

References (19)

1. Magliocca JF, Knechtle SJ,. The evolving role of alemtuzumab (Campath-1H) for immunosuppressive therapy in organ transplantation. Transplant Int. 2006; 19: 705.
2. Hale G, Xia MQ, Tighe HP, Dyer MJ, Waldmann H,. The CAMPATH-1 antigen (CDw52). Tissue Antigens 1990; 35: 118.
3. Kirk AD, Hale DA, Mannon RB, et al., Results from a human renal allograft tolerance trial evaluating the humanized CD52-specific monoclonal antibody alemtuzumab (CAMPATH-1H). Transplantation 2003; 76: 120.
4. Bloom DD, Hu H, Fechner JH, Knechtle SJ,. T-lymphocyte alloresponses of Campath-1H-treated kidney transplant patients. Transplantation 2006; 81: 81.
5. Knechtle SJ, Pirsch JDH, Fechner JJ, et al., Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant 2003; 3: 722.
6. Knechtle SJ, Vargo D, Fechner J, et al., FN18-CRM9 immunotoxin promotes tolerance in primate renal allografts. Transplantation 1997; 63: 1.
7. Thomas JM, Neville DM, Contreras JL, et al., Preclinical studies of allograft tolerance in rhesus monkeys: a novel anti-CD3-immunotoxin given peritransplant with donor bone marrow induces operational tolerance to kidney allografts. Transplantation 1997; 64: 124.
8. Hale G,. The CD52 antigen and development of the CAMPATH antibodies. Cytotherapy 2001; 3: 137.
9. Knechtle SJ, Fernandez LA, Pirsch JD, et al., Campath-1H in renal transplantation: The University of Wisconsin experience. Surgery 2004; 136: 754.
10. Barth RN, Janus CA, Lillesand CA, et al., Outcomes at 3 years of a prospective pilot study of Campath-1H and sirolimus immunosuppression for renal transplantation. Transplant Int 2006; 19: 885.
11. Hanaway MJ, Woodle ES, Mulgaonkar S, et al., Alemtuzumab induction in renal transplantation. N Engl J Med 2011; 364: 1909.
12. Racusen LC, Solez K, Colvin RB, et al., The Banff 97 working classification of renal allograft pathology. Kidney Int 1999; 55: 713.
13. Shapiro R, Basu A, Tan H, et al., Kidney transplantation under minimal immunosuppression after pretransplant lymphoid depletion with Thymoglobulin or Campath. J Am Coll Surg 2005; 200: 505. quiz A59-61.
14. Watson CJ, Bradley JA, Friend PJ, et al., Alemtuzumab (CAMPATH 1H) induction therapy in cadaveric kidney transplantation-efficacy and safety at five years. Am J Transplant 2005; 5: 1347.
15. Ciancio G, Burke GW, Gaynor JJ, et al., The use of Campath-1H as induction therapy in renal transplantation: preliminary results. Transplantation 2004; 78: 426.
16. Cai J, Terasaki PI, Bloom DD, et al., Correlation between human leukocyte antigen antibody production and serum creatinine in patients receiving sirolimus monotherapy after Campath-1H induction. Transplantation 2004; 78: 919.
17. Ciancio G, Burke GW, Gaynor JJ, et al., A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. Transplantation 2005; 80: 457.
18. Kaufman DB, Leventhal JR, Axelrod D, Gallon LG, Parker MA, Stuart FP,. Alemtuzumab induction and prednisone-free maintenance immunotherapy in kidney transplantation: comparison with basiliximab induction-long-term results. Am J Transplant 2005; 5: 2539.
19. Huang E, Cho YW, Hayashi R, Bunnapradist S,. Alemtuzumab induction in deceased donor kidney transplantation. Transplantation 2007; 84: 821.